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Abstract
Phagocytic clearance and lysosomal processing of pathogens and debris are essential functions 
of the innate immune system. However, the assessment of these functions in vivo is challenging 
because most nanoscale contrast agents compatible with non-invasive imaging techniques are 
made from non-biodegradable synthetic materials that do not undergo regular lysosomal 
degradation. To overcome this challenge, we describe the use of an all-protein contrast agent to 
directly visualize and quantify phagocytic and lysosomal activities in vivo by ultrasound imaging. 
This contrast agent is based on gas vesicles (GVs), a class of air-filled protein nanostructures 
naturally expressed by buoyant microbes. Using a combination of ultrasound imaging, 
pharmacology, immunohistology and live-cell optical microscopy, we show that after intravenous 
injection, GVs are cleared from circulation by liver-resident macrophages. Once internalized, the 
GVs undergo lysosomal degradation, resulting in the elimination of their ultrasound contrast. By 
non-invasively monitoring the temporal dynamics of GV-generated ultrasound signal in circulation 
and in the liver and fitting them with a pharmacokinetic model, we can quantify the rates of 
phagocytosis and lysosomal degradation in living animals. We demonstrate the utility of this 
method by showing how these rates are perturbed in two models of liver dysfunction: phagocyte 
deficiency and non-alcoholic fatty liver disease. The combination of proteolytically-degradable 
nanoscale contrast agents and quantitative ultrasound imaging thus enables non-invasive 
functional imaging of cellular degradative processes.
Keywords
ultrasound, contrast agents, phagocytosis, lysosomes, liver disease, reticuloendothelial system
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The reticuloendothelial system (RES), also known as the mononuclear phagocyte system, is a 
network of phagocytic immune cells that is essential for organismal development and 
homeostasis; malfunctions in this system may lead to increased susceptibility to infections1,2 and 
are associated with the pathogenesis of a variety of conditions, including neurodegeneration,3,4 
chronic liver disease5 and many others.6 Cells of the RES, such as monocytes, macrophages and 
dendritic cells, continuously sample their surroundings, mediating the recognition and clearance 
of abnormal and senescent cells, debris and foreign particulates.7,8 Additionally, they interface 
with the adaptive immune system by presenting lysosomally-processed antigens to lymphocytes 
and secreting cytokines to stimulate the proper inflammatory response.8-10 Phagocytosis and 
lysosomal degradation are thus vital processes of RES-mediated immunoregulation.
Non-invasive functional imaging of phagocytosis and lysosomal activities will enable early 
detection and monitoring of non-alcoholic fatty liver disease (NAFLD) and other conditions 
resulting from RES dysfunction. NAFLD currently affects over 25% of the global population and 
its progression is associated with chronic hepatic inflammation.11  Due to the large patient 
population and broad range of outcomes which include hepatitis, cirrhosis, fibrosis and 
hepatocellular carcinoma, rapid and non-invasive diagnostic methods are needed to stratify 
patients into defined risk groups.5,11 Ultrasound is well suited for this task due to its wide availability, 
portability, low operational costs and high tissue penetrance.12 Based on in vitro observations that 
pro-inflammatory macrophages suppress phagocytosis13 and lysosomal degradation,14,15   one 
would expect livers in patients with NAFLD to exhibit reduced accumulation and extended 
persistence of intravenously-administered nanoscale contrast agents. Indeed, clinical studies 
have confirmed the former.16,17 However, the latter cannot be evaluated with currently available 
technologies because agents compatible with non-invasive imaging modalities are typically made 
from synthetic materials which do not undergo regular lysosomal degradation.7,8
Here, we describe the use of an all-protein nanoscale contrast agent to visualize and 
quantify both phagocytic clearance and lysosomal degradation in vivo using ultrasound imaging. 
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This contrast agent is based on gas vesicles (GVs), a class of air-filled protein nanostructures 
natively formed inside certain photosynthetic microorganisms as a means to regulate buoyancy.18 
GVs comprise a rigid, 2 nm-thick protein shell allowing the free exchange of gas but preventing 
the internal condensation of liquid water, thereby forming a thermodynamically stable capsule of 
air with a hydrodynamic diameter of approximately 250 nm.19 They are easily isolated from 
cultures of their native cyanobacterial hosts20 and can be expressed heterologously in bacteria21,22 
and mammalian cells.23 Because sound waves are strongly reflected by air-water interfaces, GVs 
have been developed as contrast agents for ultrasound imaging.19, 24-27 Due to their innate stability, 
GVs are able to withstand repeated insonation without loss of contrast.19 However, when the GV 
shell is compromised by mechanical or chemical disruption, the gaseous contents it encloses 
rapidly and irreversibly dissolve into the surrounding media, leading to the elimination of 
ultrasound contrast.19,21,27
Based on their nanoscale dimensions and all-protein composition, which distinguishes 
them from other classes of ultrasound contrast agents,28-31 we hypothesized that we could use 
GVs as a contrast agent to non-invasively visualize the phagocytic and lysosomal functions of 
hepatic macrophages in vivo. Previous studies have shown that intravenously injected GVs are 
rapidly taken up by the liver.32,33 If this uptake is mediated by macrophages and the internalized 
GVs undergo lysosomal proteolysis, this would manifest in the initial transfer of ultrasound 
contrast from the bloodstream to the liver, followed by its elimination with kinetics representative 
of natural RES clearance and degradation. Measurement of these processes would thus provide 
a quantitative picture of the complete phagocytic and lysosomal degradation pathways. This rate-
based approach would improve upon previous Kupffer cell imaging techniques16,34-36 which are 
limited to the assessment of phagocytosis. In this study, we test this hypothesis by visualizing the 
temporal dynamics of GV ultrasound contrast in the blood and liver, establishing the cellular and 
molecular pathways mediating GV uptake and degradation, and developing a pharmacokinetic 
model to parametrize RES activity from hemodynamic and liver ultrasound signals. Finally, we 
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demonstrate the diagnostic utility of functional imaging of macrophage phagolysosomal activity in 
two models of liver disease: clodronate-mediated macrophage deficiency and diet-induced 
NAFLD. 
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Figure 1: Non-invasive ultrasound imaging of GV clearance and elimination in vivo. A, Diagram 
of imaging setups used to measure GV contrast in the blood and liver. Inset i, intravascular 
persistence of purified GVs was visualized by ultrafast power Doppler imaging of the brain. Inset 
ii, hepatic persistence of GVs modified to produce non-linear contrast was visualized by 
amplitude modulation imaging of the liver. B, Representative power Doppler images of a coronal 
cross section of the brain following GV injection. Scale bars, 2 mm. C-D, Normalized time 
courses of ultrafast Doppler signal enhancement in the brain (C, N = 6) and AM signal in the 
liver (D, N = 4). Dashed lines, time of GV injection (300 s); thin lines, individual trials; thick lines, 
mean; shaded areas, ± SEM. E, Representative AM images of a liver cross section following GV 
injection. Scale bars, 2 mm. F, Biodistribution of fluorescently-labeled GVs 1 h after IV injection. 
Representative fluorescence image of excised organs (left; scale bar, 10 mm). Percentage of 
total collected photons originating from each organ (right). N = 5. Error bars not shown.
Gas vesicle blood clearance, liver uptake and degradation can be monitored by ultrasound. 
We started by quantifying the kinetics of GV uptake and degradation in healthy C57BL/6 mice 
(Fig. 1a). We first visualized intravascular GVs with ultrafast power Doppler imaging, leveraging 
the ability of intravenously (IV) injected GVs to enhance blood flow contrast.25 We chose the brain 
as our target organ due to its practical advantages in mouse experiments: hemodynamic signals 
can be conveniently measured through intact skin and skull25,37 and head-fixation reduces motion 
artifacts. We acquired images of a single coronal plane at a center frequency of 15 MHz and 
frame rate of 0.25 Hz (Fig. 1b). Following a 300-s baseline, we IV injected 100 μL of purified GVs 
isolated from Anabaena flos-aquae (OD50030, corresponding to 2.1 x 1011 particles20) and tracked 
the ensuing distribution and clearance (Fig. 1c). As expected, the introduction of GVs caused a 
marked increase in hemodynamic signal, peaking at approximately 100 s after injection, and 
returning to baseline with an apparent circulation half-life of 232 s (Fig. 1c, Fig. S1). 
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Next, we quantified GV uptake and degradation in the liver by imaging this organ during 
and after IV injection (Fig. 1a). To maximize GV specificity, we injected GVs modified to produce 
non-linear ultrasound contrast27 and imaged with a non-linear amplitude modulation (AM) pulse 
sequence24 (Fig. 1, d-e). Following injection of 100 μL GVs at OD500 30, we observed the 
accumulation of non-linear contrast in the liver—reaching a maximum after approximately 10 
min—followed by a gradual loss of signal until only 10% remained at the end of one hour (Fig. 
1d). Notably, the maximum occurs just as contrast in the blood returns to baseline (Fig. S2). The 
apparent half-life of GVs in the liver—20 min—is substantially longer than their circulation time, 
and on a timescale consistent with lysosomal processing.38-40 To independently confirm liver 
uptake, we acquired fluorescence images of mouse organs excised 1h after IV injection of GVs 
labeled with a far-red fluorescent dye (Fig. 1f). In line with previous investigations of GV 
biodistribution,32,33 the liver was the dominant organ for GV uptake, emitting 81.4% of collected 
photons. The lungs (7.8%) and spleen (5.5%) had minor roles in GV clearance, while the heart 
and kidneys had no discernible role. 
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Figure 2: Liver macrophages are the primary mediators of GV clearance. A, Immunofluorescent 
confocal micrographs of 75-µm sections of liver tissue obtained from healthy mice 1h after IV 
injection of fluorescently-labeled GVs. Sections were stained with anti-F4/80 (macrophages) 
and DAPI. Scale bars, 50 μm. B, Percentage of detected GVs found within macrophage regions 
based on segmentation with ilastik. Error bars indicate ± SD. N = 3 biological replicates, 78 total 
fields of view. C, Experimental timeline. Macrophages were depleted by IV injection of 30 mg/kg 
liposomal clodronate 48 h before GV injection. D, Normalized Doppler signal enhancement time 
courses following IV injection of GVs in mice pre-treated with clodronate (red, N = 6) or saline 
liposomes (blue, N = 3). Dashed line, time of GV injection (300 s); thin lines, individual trials; 
thick lines, mean; shaded areas, ± SEM.
GVs are primarily cleared by liver macrophages. To identify the cells involved in GV clearance, 
we performed immunofluorescence imaging of liver sections obtained from mice perfused 1h after 
IV injection of fluorescently-labeled GVs (Fig. 2a). Based on the apparent active degradation of 
GVs, as suggested by the gradual decline of liver ultrasound contrast, we hypothesized that GVs 
would be taken up by Kupffer cells—resident macrophages lining the hepatic sinusoids which are 
implicated in the clearance of many nanoparticles.7 We tested this hypothesis by defining 
antibody-stained F4/80+ Kupffer cell regions through image segmentation by Ilastik41 and 
quantifying the localization of GVs with respect to these borders (Fig. S3). On average, 60% of 
GV-containing pixels resided within Kupffer cells (Fig. 2b). 
To confirm the role of Kupffer cells in GV clearance, we ablated phagocytic cells by IV 
administration of 30 mg/kg liposome-encapsulated clodronate42 (Fig. 2c). 48h later, we measured 
GV circulation times with hemodynamic ultrasound (Fig. 2d). Compared to mice treated with 
saline-filled control liposomes, clodronate-treated mice had a nearly 7-fold enhancement in GV 
circulation time, with half-life increasing from 274 s to 1670 s (Fig. S2). Our results are in line with 
previous observations that treatment with 50 mg/kg clodronate increased the circulation half-life 
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of 100 nm gold nanoparticles 13-fold.1 Taken together, our data shows that GVs are mainly filtered 
from the blood by Kupffer cells.
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Figure 3: Internalized GVs are degraded within lysosomes, resulting in loss of ultrasound 
contrast. A, Diagram of live cell confocal microscopy protocol. Murine macrophages 
(RAW264.7) expressing membrane-localized fluorescent protein (blue) were incubated with 
GVs dually-labeled with AF647 (red) and pHrodo (yellow) to track localization and pH, 
respectively. B, Representative images of a single cell at different time points following GV 
uptake. A phagosome maturation event is indicated by the white arrows. Scale bars, 10 μm (63x 
objective). C, Representative population-level images of cells pre-treated with DMSO (top) or 
100 nM bafilomycin A1 (bottom) following GV uptake. The AF647 channel is not shown. Scale 
bars, 20 μm (20x objective). D, Ratio of pHrodo to AF647 signals in images from c, normalized 
to the initial timepoint. Error bars represent ± SEM. N = 4. Welch’s t test (*: p<0.05; **: p<0.001). 
E, Diagram of uptake protocol for ultrasound imaging. RAW264.7 cells were incubated for 30 
min with GVs modified to produce non-linear signal, transferred to GV-free media for 
predetermined periods of time, and loaded into an agarose phantom for non-linear xAM 
imaging. F, Representative xAM images of cell pellets pre-treated with DMSO (top) or 100 nM 
bafilomycin A1 (bottom) at the indicated times after GV uptake. Scale bars, 1 mm. G, Time 
course of xAM signal intensity in cell pellets, normalized to the initial timepoint. Error bars 
represent ± SEM. N = 4-10 per timepoint. Welch’s t-test (*: p<0.05; **: p<0.01).
GVs are degraded in the lysosome following phagocytosis. Having established their uptake 
by liver macrophages, we next studied what happens to GVs following phagocytosis. 
Macrophages typically internalize nanoparticles into membrane-bound organelles—
phagosomes—that are then trafficked along the phagolysosomal pathway. During this maturation 
process, the phagosomes acquire v-ATPase proton pumps to acidify their contents prior to fusion 
with the lysosome;43 this low pH environment is required for lysosomal enzyme activity. To 
visualize the movement of GVs along this pathway in vitro, we incubated murine macrophages 
(RAW264.7) with a dilute suspension of GVs dually-labeled with Alexa Fluor (AF647) and pHrodo 
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Red—a pH-sensitive dye that fluoresces weakly at pH 7 and brightly at pH 3—and imaged them 
with live-cell confocal optical microscopy (Fig. 3a). Focusing on individual cells, we initially 
observed punctate spots of AF647 signal, likely corresponding to GVs concentrated within 
phagosomes, which matured over the next several minutes to produce strong pHrodo signal, 
indicating acidification of their environment (Fig. 3b). Zooming out to observe population-level 
dynamics revealed that the proportion of GVs in acidified compartments, as parametrized by the 
ratio of pHrodo to AF647 signal, grew continuously during a 1-hour incubation (Fig. 3, c-d). This 
rise was abolished when v-ATPase was inhibited by pretreatment with 100 nM bafilomycin A1 
(BafA1),44 thereby confirming that GVs undergo phagolysosomal processing in macrophages.
Lysosomal proteolysis is expected to break down the GV shell, resulting in GV collapse, 
gas dissolution and the disappearance of ultrasound contrast. To confirm this effect in vitro, we 
exposed RAW264.7 cells to GVs for 30 min. At predetermined time intervals, we detached the 
cells from their solid substrate and loaded them into an agarose phantom for imaging with a non-
linear cross-propagating amplitude modulation pulse sequence (xAM)26 (Fig. 3e). In control cells 
pretreated with 0.01% v/v dimethyl sulfoxide (DMSO), the signal declined with a half-life of 
approximately 3 h (Fig. 3, f-g). Conversely, in cells pretreated with BafA1 to block the activity of 
the pH-dependent lysosomal enzymes, we observed signal that persisted for at least 5 h without 
decay. These results confirm that GVs are digested within macrophage lysosomes in a process 
that can be monitored with non-linear ultrasound imaging. The reason that this process happens 
somewhat more slowly in vitro compared to the liver may be the accelerated rate of phagosome 
maturation in primary macrophages.45 
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Figure 4: Quantification of phagocytic and lysosomal activities in mouse liver macrophages. A, 
Proposed GV clearance pathway. Upon IV infusion, GVs are phagocytosed from the blood by 
liver-resident macrophages and degraded by lysosomal proteolysis. B, Pharmacokinetic model 
of GV clearance. Fitting this model to GV signal time courses enables quantification of 
macrophage function. Uptake and degradation rates are represented by k1 and k2, respectively, 
and kc is a correction factor that enables conversion between the two imaging modes and 
accounts for uptake in other tissues. C, Representative plot of vascular and liver ultrasound signal 
time courses in healthy mice (dashed lines) and corresponding fitted curves (solid lines). D, 
Uptake and elimination rates obtained by fitting model to data from Fig. 1, c-d. Error bars represent 
± SD. 
GV pharmacokinetics can be used to monitor disease progression. The results presented 
thus far confirm that upon IV injection, GVs are filtered from the blood by liver macrophages and 
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subsequently catabolized in the lysosome (Fig. 4a). This process can be described with a two-
compartment pharmacokinetic model comprising the blood and liver, whose rate constants 
parametrize the concurrent processes of phagocytosis and lysosomal degradation (Fig. 4b), with 
contrast enhancement linearly proportional to intact GV concentration in each compartment (Fig. 
S4).  By fitting this model to the dynamics of GV ultrasound contrast in the vasculature and liver 
in vivo, we can thus non-invasively quantify macrophage phagolysosomal function (Fig. 4c, input 
data shown in Fig. S5). The assumption that ultrasound signal time courses are representative of 
true pharmacokinetics is based on two key observations: GVs are stable under our imaging 
parameters, so changes in signal are due to active biological processes; and GVs are primarily 
taken up by liver macrophages, with increases in liver AM contrast matched by decreases in brain 
Doppler contrast. For simplicity, we further assume each process to be first-order and neglect the 
initial distribution dynamics during GV infusion by considering timepoints occurring after the peak 
in Doppler signal. Using this approach, we calculated rates of 0.167 min-1 and 0.041 min-1 for 
uptake and degradation, respectively, in healthy mice (Fig. 4d, Table S1).
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Figure 5: Monitoring disease progression by functional imaging of phagolysosomal activity. A, 
Macrophage population in response to clodronate dose. Top: Representative 
immunofluorescence confocal micrographs of liver sections labeled with anti-F4/80 
(macrophages) and DAPI. Scale bars, 50 μm. Bottom: Macrophage population determined by 
segmentation with ilastik, normalized to the mean from control livers. Error bars represent ± SD. 
N = 3 biological replicates, >100 total fields of view. Welch’s t-test (****: p<0.0001). B, 
Biodistribution of fluorescently-labeled GVs 1h after injection. Bottom: Representative 
fluorescence images of excised organs. Due to their low fluorescence, the hearts are circled 
with dashed lines. Scale bars, 10 mm. Top: Percentage of collected photons originating from 
each organ. Error bars not shown. N = 5. Welch’s t-test (*: p<0.05; **: p<0.001). C-D, 
Normalized time courses of Doppler signal enhancement in the brain (C) and AM signal in the 
liver (D) following GV injection in clodronate-treated mice. Dashed lines, time of GV injection 
(300 s); thick lines, mean; shaded areas, ± SEM. N = 4-6. E, Uptake and degradation rates 
obtained by fitting the model in Fig. 4b to each distinct combination of time courses from C and 
D, normalized to those of healthy mice. Error bars represent ± SD. Welch’s t-test (*: p<0.05; **: 
p<0.01; ***: p<0.001; ****: p<0.0001). F, Left: Timeline of NAFLD induction. Mice were fed with 
a methionine and choline deficient diet for 4 weeks, followed by an additional 3 weeks with a 
control diet. Right: Representative images of H&E stained liver sections. Scale bars, 100 µm. G-
H, Normalized time courses of Doppler signal enhancement in the brain (G) and AM signal in 
the liver (H) following GV injection in mice with NAFLD. Dashed lines, time of GV injection (300 
s); thick lines, mean; shaded areas, ± SEM. N = 4-5. I, Uptake and degradation rates obtained 
by fitting the model in Fig. 4b to the time courses in G and H, normalized to those of healthy 
(Week 0) mice. Error bars represent ± SD. Welch’s t-test (**: p<0.01; n.s: p>0.05).
Having established a method to quantify liver macrophage function, we next evaluated its 
ability to detect pathological disruption of the RES. First, we administered two doses of liposomal 
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clodronate—0.40 mg/kg and 30 mg/kg—to partially or fully deplete Kupffer cells in the liver. 
Histological evaluation confirmed that 31% of the Kupffer cell population remained at the lower 
dose, decreasing to 16% at the higher dose (Fig. 5a; Fig. S6). Interestingly, ex vivo imaging of 
organ fluorescence revealed that most GVs are still cleared by the liver (Fig. 5b). However, closer 
inspection of liver sections with immunofluorescence showed GVs tending to localize to the 
sinusoidal margins, suggesting uptake by liver sinusoidal endothelial cells (LSECs) (Fig. S7). This 
is consistent with a recent study showing that LSECs upregulate phagocytic activity upon 
depletion of nearby Kupffer cells.7 Based on these results, we expected that GVs would circulate 
longer in the blood in clodronate-treated animals due to diminished phagocytic potential, and that 
their residence time in the liver would increase due to less efficient lysosomal degradation by non-
macrophage cells. Indeed, fitting our model to the normalized hemodynamic Doppler (Fig. 5c) 
and liver AM (Fig. 5d) signal time courses yielded uptake and degradation rates substantially 
lower than those of healthy mice (Fig. 5e). Specifically, phagocytosis rates were reduced by 66% 
and 82% at the low and high doses of clodronate, while proteolysis rates were reduced by 27% 
and 57%, respectively. Notably, phagocytosis rates were proportional to the macrophage 
population.
For our second model of RES dysfunction, we imaged mice with NAFLD. This disease is 
characterized by liver infiltration of pro-inflammatory M1-polarized macrophages5,46 which have 
lower phagocytic13,17,34,47 and lysosomal activities15 than the normally anti-inflammatory Kupffer 
cells.48 We induced NAFLD by feeding mice with a methionine- and choline-deficient (MCD) 
diet5,49 and performed ultrasound imaging after 4 weeks of this treatment (Fig. 5f). Histological 
evaluation confirmed the appearance of widespread steatosis, a hallmark of NAFLD (Fig. 5f). In 
line with our hypothesis, diseased mice had significantly suppressed phagocytic and lysosomal 
functions: uptake rate was reduced by 35% while degradation rate was reduced by 58% (Fig. 5, 
g-i). We verified that these differences are not due to saturation of the smaller livers of MCD 
mice50 by GVs (Fig. S8). When we simulated therapeutic intervention by reverting to a control diet 
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for 3 additional weeks, the steatosis subsided (Fig. 5f) and phagolysosomal activity returned to 
its original level (Fig. 5, g-i). Compared to age-matched litter-mate controls, these “recovered” 
mice showed a slight decrease in degradation rate but no discrepancies in uptake rate (Fig. S9, 
Table S1). Taken together, our results demonstrate the capability of GV-enhanced ultrasound to 
non-invasively visualize macrophage malfunction as a biomarker of disease.
Conclusions
GVs are advantageously positioned to image in vivo phagolysosomal function due to their 
inherent stability at ambient conditions, susceptibility to natural proteolytic degradation and 
dependence on shell integrity for ultrasound contrast. When combined with a simple 
pharmacokinetic model, GV imaging makes it possible to parametrize macrophage activity in 
terms of phagocytosis and lysosomal degradation rates, clearly delineating healthy and disease 
states, as demonstrated in two models of RES deficiency. 
The diagnostic power of macrophage functional imaging arises from the dependence of 
phagolysosomal kinetics on cellular phenotype which, in turn, reflects the local tissue and 
inflammatory microenvironment. Moving forward, this capability could be refined by application of 
GVs engineered to display surface ligands,27 as phenotype-specific responses to certain particle-
bound domains may augment differences in degradative behavior.51 Methods to alter GV 
biodistribution would enable targeting and functional assessment of macrophages in tissues other 
than the liver. Additionally, the ability to genetically express GVs23 could enable study of 
intracellular proteolytic processes, such as autophagy and proteasomal degradation. 
To maximize the translational utility of this technology, three aspects could be improved. 
First, imaging parameters should be optimized for clinical use. In this study, we separately 
acquired ultrafast Doppler and non-linear AM images to maximize signal specificity. However, 
simultaneous multiplexed imaging of blood and liver signals would greatly streamline diagnostic 
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use. This could be accomplished by intercalating amplitude modulation images with Doppler 
images of the liver, enabling GV quantitation in both compartments with a single, stationary 
transducer. Second, while GV administration at doses similar to those used in our experiments 
does not result in acute, adverse health effects in mice,19 clinical translation would require formal 
studies of dose-limiting and long-term toxicity. In addition, to support long-term monitoring of 
individual subjects, it would be useful to better understand the immunogenicity of GVs and the 
impact of repeated injections, as the development of antibodies may skew clearance kinetics.52 
Finally, in some applications it may be useful to image GVs with other imaging modalities, such 
as magnetic resonance imaging28,29 and optical coherence tomography;53 adaptation of 
phagolysosomal imaging to these modalities would facilitate applications where the efficacy of 
ultrasound may be limited. 
 In summary, the combination of nanoscale, lysosomally-degradable contrast agents and 
quantitative ultrasound imaging enables non-invasive assessment of macrophage function as a 
disease-relevant biomarker. This technology will broaden the diagnostic capabilities of 
biomolecular ultrasound and motivate further methods for non-invasive characterization of cellular 
function.
Methods
GV preparation and quantification
Native gas vesicles (GVs) were isolated from Anabaena flos-aquae as previously described.20 
Concentrations were measured by optical density (OD) at 500 nm using a spectrophotometer 
(NanoDrop ND-1000, Thermo Scientific). Stripped GVs were prepared by treatment of native GVs 
with 6M urea solution followed by two rounds of centrifugally-assisted flotation and removal of the 
subnatant.20 Fluorescently-labeled gas vesicles were prepared by mixing GVs at OD 10 in 1x 
phosphate-buffered saline (PBS) with 6 μM Alexa Fluor 647 NHS Ester (Invitrogen, prepared as 
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10 mM solution in dimethyl sulfoxide). Dually-labeled GVs were prepared by mixing GVs at OD10 
with 6 μM pHrodo Red succinimidyl ester (Invitrogen, prepared as 10 mM solution in dimethyl 
sulfoxide) and 18 μM Alexa Fluor 647 NHS Ester (Invitrogen, prepared as 10 mM solution in 
dimethyl sulfoxide). After rotating in the dark at 25°C for 1 h, the reactions were quenched with 
Tris-HCl. Prior to use, all GVs were buffer exchanged into 1x PBS by two rounds of overnight 
dialysis through a regenerated cellulose membrane (12-14 kD MWCO, Repligen).
Cell culture
RAW264.7 (TIB-71) and HEK293T (CRL-3216) cells were ordered from the American Type 
Culture Collection (ATCC). Cells were cultured on tissue culture treated 10-cm dishes in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% Fetal Bovine Serum and 1% 
penicillin/streptomycin. 
Lentiviral transduction. Plasmid constructs were designed with SnapGene (GSL Biotech) and 
assembled with Gibson Assembly reagents from New England Biolabs. Briefly, mWasabi54 was 
inserted downstream of a 20-AA palmitoylation tag from GAP43 and expressed under the EF-1α 
promoter (gift from Dan I. Piraner55). This plasmid was then transfected along with third-
generation lentiviral vector and helper plasmids (kind gifts from the laboratory of David Baltimore) 
into HEK293T cells using polyethyleneimine (PEI). Following a 12 h incubation, PEI-containing 
media was replaced with fresh media supplemented with 10 mM sodium butyrate (Sigma Aldrich). 
Viral particles were concentrated 48 h later via ultracentrifugation. RAW264.7 cells were 
transduced by spinfection. Briefly, concentrated virus was added to non-tissue culture treated 24-
well plates coated with RetroNectin (Takara Bio). Following centrifugation (2,000xg, 2h), 4e5 
RAW264.7 cells in 1 mL media were added to each well. The plates were spun again at 900xg 
for 50 min before transferring to the incubator. The brightest 10% of cells were selected with a 
BD FACSAria III (BD Biosciences) at the City of Hope Analytical Cytometry Core Facility. 
Preparation of fibronectin-treated cover slips. Ethanol sterilized square (22 mm x 22 mm) #1.5H 
glass cover slips (Thorlabs) were individually placed into the wells of a 6-well plate and immersed 
Page 21 of 36
ACS Paragon Plus Environment
ACS Nano
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
in 2 mL PBS containing 10 μg fibronectin from bovine plasma (Sigma Aldrich) for 2h at room 
temperature. The fibronectin solution was then aspirated and the plates stored at 4°C until use. 
Sterile glass-bottom 35mm dishes (MatTek) were similarly coated with 2.5 μg fibronectin in 500 
μL PBS. 
Animal preparation and disease models
All in vivo experiments were performed on male C57BL/6J mice (The Jackson Laboratory) under 
protocols approved by the Institutional Animal Care and Use Committee at the California Institute 
of Technology. 
Macrophage depletion. Liposome-encapsulated clodronate (Clodrosome, Encapsula 
NanoSciences) was administered through the lateral tail vein 48 h prior to imaging. Mice receiving 
a dose of 30 mg/kg were injected with undiluted liposome suspension, while mice receiving the 
lower dose of 0.40 mg/kg were injected with liposomes diluted 1:100 with sterile saline. Control 
mice were injected with the equivalent volume of undiluted PBS liposomes (Encapsome, 
Encapsula NanoSciences). 
Diet-induced nonalcoholic fatty liver disease. 8-week old mice were free fed with either a 
methionine and choline deficient diet (5ADJ, TestDiet) or control diet (5CC7, TestDiet) for up to 4 
weeks. Afterwards, all mice were fed the control diet for an additional 3 weeks. Because this 
dietary protocol often results in dramatic weight loss, the mice were monitored weekly for signs 
of adverse health. GV pharmacokinetics were measured at 2 weeks, 4 weeks and at the 
conclusion of the study. Immediately after ultrasound imaging, the mice were fixed via sequential 
transcardial perfusion of PBS and 10% neutral buffered formalin (Sigma Aldrich), and the livers 
were removed for histological assessment by the UCLA Translational Pathology Core Laboratory. 
Briefly, 4-µm sections were cut from paraffin-embedded organs, stained with hematoxylin & eosin, 
and imaged at 20x with a Leica Aperio slide scanner.
Ultrasound imaging
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Transcranial ultrafast Doppler imaging. Mice (8-10 weeks old) were maintained under 1.5% 
isoflurane anesthesia on a temperature-controlled imaging platform with a rectal probe (Stoelting 
Co.). Following head depilation (Nair) and insertion of a catheter with a 30-g needle into the lateral 
tail vein (fixed in place with GLUture), the mice were head-fixed in a stereotaxic frame inside a 
light- and sound-proofed box on an optical table. A 16 MHz transducer (Vermon) connected to a 
programmable ultrasound scanner (Verasonics Vantage) was coupled to the head through a 
column of ultrasound gel (centrifuged at 2000xg, 10 min to remove bubbles). The transducer was 
positioned to capture a full coronal section at an arbitrary plane along the rostrocaudal axis. Once 
the internal temperature of the mouse stabilized at 37°C, power Doppler images were acquired 
every 4 s for up to 60 min using a previously described functional ultrasound script with slight 
modifications.25 Briefly, the pulse sequence consisted of 11 tilted plane waves (varying from -10 
to 10 degrees), each containing 8-half-cycle emissions at a voltage of 15V (900 kPa peak positive 
pressure measured in free water tank). An ensemble of 250 coherently compounded frames, 
collected at a framerate of 500 Hz, was then processed through a singular value decomposition 
filter to isolate blood signals from tissue motion and generate a single power Doppler image. 300 
s after the start of imaging, 100 μL OD30 native GVs were infused over 10 s by syringe pump. 
Pixel-wise signal enhancement was calculated as the ratio of intensity at each time point relative 
to its mean intensity in the first 75 frames. Time courses were then extracted by averaging signal 
enhancement within a manually defined region of interest encompassing the whole brain, 
processed with a 10-sample moving mean filter and normalized to the global maximum.
Liver amplitude modulation imaging. Mice (10-14 weeks) were maintained under 2% isoflurane 
anesthesia on a mouse heating pad controlled by a rectal probe (TCAT-2LV, Physitemp 
Instruments). After depilation of the abdomen (Nair) and insertion of a 30-g tail vein catheter, the 
mice were secured in a supine position with surgical tape. Ultrasound imaging was performed 
with an 18 MHz, 128-element linear array transducer (L22-14v, Verasonics) mounted on a 
custom-made manual translation stage and positioned such that the liver was at approximately 8 
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mm in depth. Once the internal temperature of the mouse stabilized at 37°C, B-mode and 
amplitude modulation images were simultaneously acquired every 4 s for up to 90 min. All images 
were reconstructed from 128 focused beam ray lines. Each ray line was transmitted at 18 MHz 
from a 32-element active aperture with a focal depth of 8 mm and peak positive pressure of 600 
kPa (measured in free water tank). B-mode images were reconstructed from a single pulse, while 
amplitude modulation was implemented by first transmitting a single pulse from the full active 
aperture, followed by two pulses where the even and odd elements in the active aperture are 
sequentially silenced.24 Stripped GVs (OD 30, 100 μL) were manually injected as a bolus after 
300 s. Image processing and display were performed by internal Verasonics programs. Time 
courses were calculated as the average signal intensity within a manually defined rectangular 
region of interest encompassing the liver. To enable comparison, the time courses were smoothed 
by robust locally weighted-regression using linear least squares, baseline corrected with respect 
to the first 75 time points and normalized to the global maximum.
In vitro macrophage imaging. Wild-type RAW264.7 cells were seeded onto fibronectin-coated 
cover slips (2e6 cells/2mL DMEM). After 24 h, the culture media was exchanged with fresh DMEM 
containing bafilomycin A1 (100 nM) or vehicle (0.01% v/v DMSO). Media of the same composition 
was used for all subsequent steps. Following a 1 h pretreatment, a GV suspension composed of 
320 μL fresh media and 80 μL stripped GVs (OD10 in PBS) was dropped at the center of a UV-
sterilized Parafilm-lined 6-well plate and a cover slip was floated on top, cell-side down. This GV 
suspension was freshly prepared immediately prior to uptake. After incubation at 37°C for 30 min, 
the cover slips were transferred to pre-warmed fresh media and incubated for the desired amount 
of time. The media was then aspirated and the cover slips were gently washed once with 2 mL 
room temperature PBS. Cells were detached with 500 μL 0.25% trypsin-EDTA (Genesee 
Scientific), neutralized with 1 mL media, and pelleted by centrifugation (300xg, 5 min, 4°C). From 
this point on, special care was taken to minimize exposure of the cells to temperatures above 
4°C. The pellet was washed once with 1.4 mL ice-cold PBS and resuspended in 50 μL cold serum-
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free DMEM with 25 mM HEPES before loading into an ultrasound phantom (1% agarose in PBS). 
Cell densities were manually counted by hemocytometer. 
The phantoms were imaged with a 128-element linear array transducer (L10-4v, 
Verasonics) mounted on a custom manual translation stage using a previously described cross-
propagating amplitude modulation pulse sequence26 that was modified to acquire single frames. 
Briefly, each frame consisted of 64 ray lines transmitted at 4V (400 kPa peak positive pressure in 
water) and 6 MHz from a 65-element aperture. Within the active aperture, amplitude modulation 
was implemented by sequentially sending a plane wave angled at 19.5° from the first 32 elements, 
a plane wave angled at -19.5° from the last 32 elements, followed by simultaneous emission of 
both plane waves. The first 3 frames were saved along with a post-collapse image (after 10 
insonations at 30 V). Signal intensities were extracted from manually selected circular regions of 
interest with diameters of 1.8 mm, baseline corrected by subtraction of signal from the post-
collapse image, and adjusted for cell density. The time courses from each run were then 
normalized to the mean intensity from the samples harvested immediately after uptake (t=0). 
GV contrast measurement. Phantoms were constructed as previously described.19 Briefly, 
phantoms were made by embedding stripped GVs in 1% agarose in PBS and imaged with the 
same parameters used for liver imaging. Signal intensities were extracted from manually defined 
regions of interest.
Fluorescence imaging
Whole organ fluorescence. Mice were prepared as described above for transcranial neuroimaging, 
with the only modification being that the GVs were fluorescently-labeled with Alexa Fluor 647. 
Ninety minutes after GV injection, the mice were transcardially perfused with 30 mL of cold 
heparinized PBS (10 U/mL, Sigma Aldrich). The heart, lungs, kidneys, spleen, and liver were then 
carefully excised and stored in ice-cold Fluorobrite DMEM (Gibco) prior to analysis. Images were 
acquired on a Bio-Rad ChemiDoc MP imaging system using red epi-illumination and a 695/55 nm 
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filter with an exposure time of 0.5 s. Integrated intensities were then calculated using the built-in 
“Analyze Particles” function in FIJI. 
Immunofluorescence. Mice were prepared as described above for whole organ fluorescence. 
Ninety minutes after GV injection, the mice were transcardially perfused with 30 mL of cold 
heparinized PBS, followed immediately by 20 mL 10% neutral buffered formalin. The liver and 
spleen were removed and immersed in formalin overnight (4°C). Each organ was then sectioned 
with a vibrating microtome (75 μm, Compresstome, Precisionary Instruments). Slices were 
blocked and permeabilized (2h, rt) with PBS containing 10% goat serum (Sigma Aldrich), 0.2% 
Triton X-100 (Fisher Scientific), and 0.1% sodium azide (Sigma Aldrich). Each slice was stained 
for macrophages with rat anti-mouse F4/80 (BioLegend, 1:200 dilution, overnight, 4°C) and Alexa 
Fluor 594 goat anti-rat IgG secondary antibody (2h, rt, 1:400 dilution). The sections were mounted 
with ProLong Diamond with DAPI (Invitrogen) and allowed to harden overnight before imaging 
with a Zeiss LSM 800 confocal microscope through a 10x or 20x objective. Imaging parameters 
prioritized signal specificity over speed. 
Confocal microscopy images of entire liver slices were background subtracted in FIJI (20 
px, rolling ball method). Randomly selected 500 px by 500 px regions of interest—simulating the 
sampling of arbitrary fields of view –were exported to Ilastik41 for processing. The “Density 
Counting” workflow was used to count macrophages (Fig. S6). Images were also segmented into 
macrophage and non-macrophage regions with the “Pixel Classification” workflow and loaded into 
MATLAB for colocalization analysis (Fig. S3). 
Live-cell imaging. 1e5 RAW264.7 cells expressing palmitoylated mWasabi were seeded on 
fibronectin-treated 35mm glass-bottom dishes. After 24 h, the culture media was exchanged with 
serum-free Fluorobrite DMEM containing 25 mM HEPES and either 100 nM bafilomycin A1 
(Cayman Chemical) or vehicle (0.01% v/v DMSO). Following a 1 h incubation, this media was 
replaced with a 200 μL freshly-prepared suspension of OD 1.2 dually-labeled GVs. The well was 
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then sealed with a UV-sterilized 18mm circular glass cover slip and inverted for 5 min at 37°C to 
allow for contact and uptake. 
Laser scanning confocal images were acquired every 2 min for 1h on a Zeiss LSM 800 
microscope with a large incubation chamber maintained at 37°C. High magnification images were 
acquired through a 63x oil immersion objective. Population level images were acquired through a 
20x objective. In both cases, acquisition parameters were set to optimize speed. Image files were 
loaded into FIJI, visualized by maximum intensity projection, de-speckled with a 1-px median filter 
and quantified by integration of signal intensities across the entire field of view.
Pharmacokinetic modeling
A two-compartment pharmacokinetic model was implemented in MATLAB as the following system 
of ordinary differential equations:
(1)
𝑑𝐵
𝑑𝑡 =  ― 𝑘1𝐵
(2)
𝑑𝐿
𝑑𝑡 = 𝑘1𝑘𝑐𝐵 ― 𝑘2𝐿
Where B represents GV contrast in the blood and L represents GV contrast in the liver. These 
variables were then directly parametrized with normalized Doppler and AM signal time courses, 
respectively, and the constants were derived by non-linear least squares curve fitting with initial 
values of 0 and bounds of 0 to 1. k1 and k2 represent rates of phagocytosis and lysosomal 
degradation, respectively. kc is a constant relating the blood Doppler signal to the liver nonlinear 
signal. Input data were all distinct combinations of Doppler and AM time courses from each 
biological condition. Output values are tabulated in Table S1.
Statistical analysis
Sample sizes were chosen based on preliminary experiments to yield sufficient power for the 
proposed comparisons. Statistical methods are described in applicable figure captions. 
Data and code availability 
All gas vesicles, plasmids, data and code are available from the authors upon reasonable 
request. 
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